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Background: The BioFreedom (BF) Biolimus A9 (BA9) coated stent (Biosensors Int., Singapore) is a new generation polymer-free drug-eluting stent 
encompassing a 316L stainless steel platform modified with a proprietary surface treatment resulting in a selectively micro-structured abluminal 
surface. This technology allows adhesion of a potent antiproliferative agent (BA9) to the stent’s abluminal surface and further controlled release 
of the drug without the use of a polymer or binder. We report the results of the first-in-man evaluation of the BF BA9-coated stents, which were 
available in 2 different formulations: standard dose (SD: 15.6μg/mm) and low dose (LD: 7.8μg/mm). 
Methods: 182 pts w/ single lesion were included in the prospective, multicenter (4 sites in Germany), randomized (1:1:1 ratio) BIOFREEDOM 
trial. Pts were treated with the BF-SD (n=60), BF-LD (n=62) vs. Taxus paclitaxel-eluting stents (PES) (n=60). Lesion criteria were native vessels 2.25-
3.0mm in diameter, and <14mm in length. Overall, pts were divided into 2 cohorts w/ same randomization ratio: 1st cohort (n=75), enrolled in 
Sep/08-Jan/09 (angiographic FU at 4-month); and 2nd cohort (n=107), enrolled in Jan-Jun/09 (angiographic FU at 12-month). Primary endpoint 
was in-stent late lumen loss (LLL) (non-inferiority, margin = 0.24mm) at 12-month FU (2nd cohort). 
Results: Baseline characteristics were comparable among the 3 groups; 38% of lesions were located in LAD, and all pts achieved angiographic 
success. At 4-month FU (1st cohort), QCA results showed significant decrease in in-stent LLL w/ BF-SD and BF-LD vs. PES: 0.08 and 0.12 vs. 0.37mm 
(p<0.0001 for BF-SD vs. PES; p=0.002 for BF-LD vs. PES); at 12-month, similar results were found including in-stent LLL of 0.17 and 0.22 vs. 
0.35mm for BF-SD and BF-LD vs. PES (p=0.001 for BF-SD vs. PES; p=0.21 for BF-LD vs. PES - non-inferiority). 
Conclusions: The novel BF polymer-free BA9-coated stents showed excellent acute results, and sustained efficacy through 12-month FU. 
Specifically, the BF-SD met the primary endpoint of non-inferiority in LLL (a surrogate of neointimal proliferation) compared to polymeric PES. Larger 
trials with longer-term FU are warranted.
